Dear Dr. Gutman:

Please refer to your supplemental new drug application dated and received April 30, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Afinitor® (everolimus) Tablets.

We acknowledge receipt of your submissions dated June 26, July 7, 8, 13, 14, 16, August 6, 24, 27, September 1, 15, and October 26, and 28, 2010.

This new drug application provides for the use of Afinitor® (everolimus) for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) who require therapeutic intervention but are not candidates for curative surgical resection.

We have completed the review of this supplemental application, as amended. According to the regulations for accelerated approval, we have concluded that adequate information has been presented to approve Afinitor® (everolimus) for use as recommended in the enclosed labeling text. Accordingly, the application is approved under 21 CFR 314 Subpart H. Approval is effective on the date of this letter. Marketing of this drug product and related activities are to be in accordance with the substance and procedures of the referenced accelerated approval regulations.

Reference ID: 2857488
CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug for this indication has an orphan drug designation, you are exempt from this requirement.

POSTMARKETING REQUIREMENTS UNDER 21 CFR 314.510 (SUBPART H)

Products approved under the accelerated approval regulations, 21 CFR 314.510, require further adequate and well-controlled studies to verify and describe clinical benefit. We remind you of your post marketing requirements specified in your submission dated October 26, 2010. These requirements, along with any completion dates agreed upon, are listed below.

PMR 1700-1:
Submit the final report (at least 4 years of follow-up) and datasets from M2301, a randomized, double-blind, placebo-controlled, multi-center phase 3 trial evaluating treatment with everolimus versus placebo in patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS).

The timetable you submitted on October 26, 2010, states that you will conduct this trial according to the following schedule:

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Final Protocol Submission:</td>
<td>January 2011</td>
</tr>
<tr>
<td>Trial Completion:</td>
<td>September 2014</td>
</tr>
<tr>
<td>Final Report and Dataset Submission:</td>
<td>March 2015</td>
</tr>
</tbody>
</table>
PMR 1700-2:
Submit the long-term (at least 5 years) follow-up efficacy and safety data from C2485, a single-arm, single-institution, phase 2 trial evaluating treatment with everolimus in patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS)

The timetable you submitted on October 26, 2010, states that you will conduct this trial according to the following schedule:

- Final Protocol Submission: March 2011
- Trial Completion: March 2014
- Final Report and Dataset Submission: November 2014

Final reports should be submitted to this NDA as a supplemental application. For administrative purposes, all submissions relating to these postmarketing requirements must be clearly designated "Subpart H Postmarketing Requirements."

We also remind you that, under 21 CFR 314.550, after the initial 120 day period following this approval, you must submit all promotional materials, including promotional labeling as well as advertisements, at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.

POSTMARKETING REQUIREMENTS UNDER 505(o)

Section 505(o)(3) of the FDCA authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

During the review of Afinitor® (everolimus) for SEGA, we became aware that the potential effect of Afinitor® (everolimus) on growth in the pediatric patient population was not adequately assessed because no long-term follow up data is available. Non-clinical data indicates that there exists dose-related delayed attainment of developmental landmarks including delayed eye-opening, delayed reproductive development in males and females, and increased latency time during the learning and memory phases in juvenile rat toxicity studies. Furthermore, cases of low testosterone concentrations associated with high levels of follicle-stimulating hormone have been reported in the broader everolimus transplant program and no specific evaluation for the presence of hypogonadism has been performed. Therefore, we consider this information to be “new safety information” as defined in section 505-1(b)(3) of the FDCA.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to identify an unexpected serious risk of delayed attainment of developmental landmarks, delayed growth, and hypogonadism in the pediatric population.

Furthermore, the new pharmacovigilance system that FDA is required to establish under section 505(k)(3) of the FDCA has not yet been established and is not sufficient to assess these serious risks.

Reference ID: 2857488
Finally, we have determined that only a clinical trial (rather than a nonclinical or observational study) will be sufficient to identify an unexpected serious risk of delayed attainment of developmental landmarks, delayed growth, and hypogonadism in the pediatric population.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following:

**PMR 1700-3:**
To evaluate the potential for serious risk of adverse long-term effects of Afinitor® (everolimus) on growth for pediatric patients, submit long-term follow-up data on patients enrolled on M2301, a randomized, double-blind, placebo-controlled, multi-center phase 3 trial evaluating treatment with Afinitor® (everolimus) versus placebo in patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS).

All patients must be evaluated for growth and development milestones annually while still treated in the extension phase of M2301 (minimum of 4 years after randomization of the last patient). Evaluations must include the following: growth as measured by weight, height (measured with a stadiometer), height standard deviation scores (SDS), height velocity, height velocity SDS, age at thelarche (females), age at adrenarche (males), age at menarche (females), and Tanner Stage progression. Results of each evaluation must be documented. Luteinizing and follicle stimulating hormones (LH, FSH), and testosterone levels in boys and LH, FSH and estradiol levels in girls must be measured in patients who have not developed secondary sexual characteristics by age 13 in girls and 14 in boys. Descriptive statistics (including mean and standard deviation values) of on-study data for growth velocity must be presented. Growth velocity during the trial should be compared with growth velocity at baseline (if pre-baseline data are available). Provide analyses of height and weight data that assess measures of central tendency and outlier analyses using height and weight z-scores.

The timetable you submitted on October 26, 2010, states that you will conduct this trial according to the following schedule:

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Final Protocol Submission</td>
<td>January 2011</td>
</tr>
<tr>
<td>Trial Completion Date</td>
<td>September 2014</td>
</tr>
<tr>
<td>Final Report and Dataset Submission</td>
<td>March 2015</td>
</tr>
</tbody>
</table>

**PMR 1700-4:**
To evaluate the potential for serious risk of adverse long-term effects of Afinitor® (everolimus) on growth for pediatric patients, submit long-term follow-up data on patients enrolled on C2485, a single-arm, single-institution, phase 2 trial evaluating treatment with Afinitor® (everolimus) in patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS).
All patients must be evaluated for growth and development milestones annually while still treated in the extension phase of C2485 (at least 5 years). Evaluations must include the following: growth as measured by weight, height (measured with a stadiometer), height standard deviation scores (SDS), height velocity, height velocity SDS, age at thelarche (females), age at adrenarche (males), age at menarche (females), and Tanner Stage progression. Luteinizing and follicle stimulating hormones (LH, FSH), and testosterone levels in boys and LH, FSH and estradiol levels in girls must be measured in patients who have not developed secondary sexual characteristics by age 13 in girls and 14 in boys. Descriptive statistics (including mean and standard deviation values) of on-study data for growth velocity must be presented. Growth velocity during the trial should be compared with growth velocity at baseline (if pre-baseline data are available). Provide analyses of height and weight data that assess measures of central tendency and outlier analyses using height and weight z-scores.

The timetable you submitted on October 26, 2010, states that you will conduct this trial according to the following schedule:

- **Final Protocol Submission:** March 2011
- **Trial Completion Date:** March 2014
- **Final Report and Dataset Submission:** November 2014

Submit clinical protocols to your IND, with a cross-reference letter to this NDA. Submit all final reports to your NDA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate:

- **REQUIRED POSTMARKETING PROTOCOL UNDER 505(o)**
- **REQUIRED POSTMARKETING FINAL REPORT UNDER 505(o)**
- **REQUIRED POSTMARKETING CORRESPONDENCE UNDER 505(o)**

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 314.81(b)(2)(vii) requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.
As required by 21 CFR 314.550, submit all promotional materials at least 30 days before the intended time of initial distribution of labeling or initial publication of the advertisement. Send two copies of all promotional materials directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

**LETTERS TO HEALTH CARE PROFESSIONALS**

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program  
Office of Special Health Issues  
Food and Drug Administration  
10903 New Hampshire Ave  
Building 32, Mail Stop 5353  
Silver Spring, MD 20993

**REPORTING REQUIREMENTS**

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Christy Cottrell, Regulatory Project Manager, at (301) 796-4256.

Sincerely,

{See appended electronic signature page}  
Robert Justice, M.D., M.S.  
Director  
Division of Drug Oncology Products  
Office of Oncology Drug Products  
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT L JUSTICE
10/29/2010